Literature DB >> 9341987

Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the Fc gammaRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia.

G A Denomme1, T E Warkentin, P Horsewood, J A Sheppard, M N Warner, J G Kelton.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder caused by heparin-dependent IgG (HIT-IgG) that recognizes a complex of heparin and platelet factor 4 (PF4), leading to platelet activation via the platelet Fc gammaIIa receptors (Fc gammaRIIa). Not all patients who generate HIT-IgG in response to heparin develop HIT, however, possibly because of observed differences in the ability of platelets from healthy individuals to be activated by HIT sera. It is known that a polymorphism in the platelet Fc gammaRIIa plays an important role in determining platelet reactivity to murine platelet-activating monoclonal antibodies of the IgG1 subclass: homozygous arg131 ("high responder" or HR) platelets respond well, and homozygous his131 ("low responder" or LR) platelets respond poorly, respectively, to these murine monoclonal antibodies. We sought to determine whether the differing risk for HIT among patients who receive heparin, as well as the variable platelet reactivity to HIT sera, could be explained by preferential activation by HIT-IgG of platelets bearing a particular Fc gammaRIIa phenotype. We found that the LR Fc gammaRIIa gene frequency was significantly overrepresented among 84 HIT patients, compared with that of 264 control subjects (0.565 versus 0.471; p = 0.03). We studied the subclass distribution of HIT-IgG against its major antigen, heparin/PF4 complexes, and found that 55 of 61 (90%) HIT sera expressed IgG1 antibodies either alone (n = 47) or in combination with IgG2 (n = 5) or IgG3 (n = 3). We then compared the platelet-activating profile of HIT sera with murine platelet-activating monoclonal antibodies. As expected, the murine IgG1 monoclonal antibodies preferentially activated platelets from homozygous HR individuals. In contrast, however, the LR homozygous platelets exhibited the greatest reactivity to HIT sera that contained predominantly anti-heparin/PF4 antibodies of the IgG1 subclass. We conclude that the significant overrepresentation of the LR (his131) gene among patients with HIT may be explained by the preferential activation of LR Fc gammaRIIa platelets by HIT antibodies of the IgG1 subclass, which is the predominant immunoglobulin subclass generated in HIT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9341987     DOI: 10.1016/s0022-2143(97)90022-6

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  14 in total

Review 1.  Functions of the Fc receptors for immunoglobulin G.

Authors:  B K Flesch; J Neppert
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

Review 3.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; D B Cines
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 4.  Fundamental concepts in the pathobiology of heparin-induced thrombocytopenia.

Authors:  J L Januzzi; I K Jang
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 5.  Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia.

Authors:  J M Walenga; W P Jeske; H L Messmore
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

6.  PF4/heparin complexes are T cell-dependent antigens.

Authors:  Shayela Suvarna; Lubica Rauova; Emily K E McCracken; Christina M Goss; Bruce S Sachais; Steven E McKenzie; Michael P Reilly; Michael Dee Gunn; Douglas B Cines; Mortimer Poncz; Gowthami Arepally
Journal:  Blood       Date:  2005-04-21       Impact factor: 22.113

7.  Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.

Authors:  Adam M Boruchov; Glenn Heller; Maria-Concetta Veri; Ezio Bonvini; Jeffrey V Ravetch; James W Young
Journal:  J Clin Invest       Date:  2005-09-15       Impact factor: 14.808

Review 8.  Heparin induced thrombocytopenia: diagnosis and management update.

Authors:  I Ahmed; A Majeed; R Powell
Journal:  Postgrad Med J       Date:  2007-09       Impact factor: 2.401

Review 9.  Benefit-risk assessment of treatments for heparin-induced thrombocytopenia.

Authors:  Harry Messmore; Walter Jeske; William Wehrmacher; Jeanine Walenga
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Critical role for mouse marginal zone B cells in PF4/heparin antibody production.

Authors:  Yongwei Zheng; Mei Yu; Andrew Podd; Liudi Yuan; Debra K Newman; Renren Wen; Gowthami Arepally; Demin Wang
Journal:  Blood       Date:  2013-03-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.